We also explored the ability of CXCR4 to predict the efficacy of immunotherapy in NSCLC patients based on CXCR4 mRNA expression and corresponding anti-PD-1 immunotherapy response in another immunotherapy cohort. Here, CXCR4 is linked to non-small cell lung carcinoma.